ASCO 2023

CDK4/6i in EBC: Have abema and ribo arrived in the early setting? Insights from North America and Europe

Discussions and controversies on social-media: what is the impact of science-twitter discussions on the everyday practice in oncology?

Sonia trial: How does the new data change clinical practice - or does it at all? Insights from Italy, United States and Germany.

ADC revolution: How can the new results be integrated in clinical practice? Which studies are in sight and which ones do we need in the future?

PART2: Trying to understand optimal therapy for pre-menopausal women - promising results, but still long way to go!

Expanding CDK4/6i therapy in EBC: How to select patients for the right therapy?

PART1: How to de-escalate chemotherapy? What is the best strategy to identify patients who don´t need chemotherapy?

CDK4/6 inhibitors in EBC: Amazing data, but longer follow up needed!

Chemotherapy de-escalation in HER2+ patients: Consequences of the PHERGain data on daily practice?!

Data from Meta-Analyses of almost 15k Patients: Who benefits from ovarian function suppression?

New data on Ribocilib in adjuvant setting EBC: What does it change immediately, what changes are expected in the future? Perspectives from Europe and Northern America

1/3 of patients with HER2+ in future without chemotherapy?

Tumor-informed ctDNA likely prognostic for relapse in ER positive and HER2 negative EBC

Ribociclib improves iDFS

TILs are prognostic but not predictive in HER2+ EBC

Checkpoint inhibition in endometrial cancer: new therapy algorithms needed

Response adapted, chemotherapy-free option in HER2+ EBC

TILs subtypes are associated with clinical features and prognosis in HR+/HER2- BC

De-escalation of CT for early BC

A challenge for clinical management

Practice changing or not quite yet?

Analyses of ctDNA in PENELOPE-B: Test methods are increasingly accurate

TILs in HER2+ disease - prognostic, but not enough to deescalate

Discussions on CDK4/6 inhibitors in EBC

Ovarian function - Ovarian suppression not necessary in young patients?

First data with adjuvant ribociclib

My EBC highlights from ASCO23

White blood cells with increasing prognostic relevance? Data from the GeparNuevo Study

Another proof of efficacy of immunotherapy in advanced TNBC

PHERGain opens the possibility to avoid chemotherapy in HER2+ breast cancer

Chemo-immunotherapeutic signals especially in HER2low possibly predictive of chemotherapy response in EBC

Palbociclib after Palbociclib might not be the best option

From PENELOPE-B to SURVIVE

Ribociclib has arrived in the adjuvant setting

Early follow-up shows clear benefit

SOC of ovarian ablation confirmed in meta-analysis.

Can we preserve our patients form chemotherapy?

10 years update on ShortHER

More CDK4/6 options for EBC patients

Young patients benefit from ovarian suppression

Czy wystarczy, aby zmienić standardy?

SOC der ovarialen Ablation in der Metaanalyse bestätigt

NATALEE nicht überraschend aber überzeugend positiv

Von PENELOPE-B zur SURVIVE

Primele date cu ribociclib adjuvant

TILs Subtypen sind assoziiert mit klinischen Merkmalen und Prognose beim HR+/HER2- BC

Tumor-informed ctDNA wahrscheinlich prognostisch für einen Rückfall beim ER positive und HER2 negative eBC

Kolejny dowód na skuteczność immunoterapii w zaawansowanym raku trójujemnym

I miei punti salienti di ASCO23

Chemo-IO Signale bei HER2low prädiktiv für Ansprechen der Chemotherapie

Palbociclib después de Palbociclib podría no ser la mejor opción

TILs sind prognostisch aber nicht prädiktiv beim HER2+ eBC

PHERGain abre la posibilidad de evitar la quimioterapia en el cáncer de mama HER2+

Response adaptierte, Chemotherapie-freie Option beim HER2+ eBC

Eine Herausforderung für viele Patienten, wenig Doktoren

Eine Herausforderung für das klinische Management

TILs w rakach HER2+ - znaczenie rokownicze, ale nie droga do deeskalacji leczenia

Ovar Funktion - Ovarielle Supression verzichtbar bei jungen Patientinnen?

1/3 der Patientinnen mit HER2+ zukünftig ohne Chemotherapie?

Molecular imaging for endocrine responsivness

Updates on ADCs in metastatic breast cancer

CDK4/6 i beyond CDK4/6 i: one more piece to the puzzle

The start of precision medicine in HR+ breast cancer

Continued OS benefit for Sacituzumab Govitecan

E-Health Applications in Oral Cancer Therapy

What is the optimal therapie sequence for HR+ MBC patients?

Mises à jour sur les ADC dans le cancer du sein métastatique

Aggiornamenti sugli ADC nel carcinoma mammario metastatico

CDK4/6i dopo CDK4/6i, un altro pezzo del puzzle: lo studio PALMIRA

CDK4/6i in first line and beyond & Biomarkers

CDK4/6 Sequencing? ESR-1 not ready for prime time? Palbo rechallenge?

The value of eHealth

Update ADC efficacy

PSA nadir 6 month after Radiotherapy is strong prognostic marker for survival

Metastasis-directed for prostate cancer

LuPARP combination study: LuPSMA and Olaparib in mCRPC

Over-staging of bone scan compared with PSMA PET/CT

Reassuring real-world data!

Part2: Important update on testosterone-recovery

TALAPRO-2: Results and controversies

AI for prediction in local prostate carcinoma

Part 1: Important update on testosterone-recovery

Intensified or de-intensified therapy in mHSPC

PRL-02: Intramuscular arbiraterone

PAPR-inhibitors: Patient-selection matters!

ARASEC: ADT + Daralutamide for mHSPC

DEAR trial: real-world comparator analyses of ARIs

PEACE 1 - results and controversies

Confirming results for PARPi in mCRPC

LuPARP studien: 177-Lu-PSMA och olaparib vid mCRPC

PSA nadir 6 månader efter radioterapi är en prognostisk markör för överlevnad

Skelettscintigrafi ospecifikt jämfört med PSMA PET-CT

Intensifierad eller de-intensifierad behandling vid mHSPC?

Επιβεβαίωση αποτελεσμάτων για το PARPi στο mCRPC

PARP-inhibitors: La selección de pacientes es importante

PARPi in PCa: more genetic testing is required as PRO data demand better patient selection

Triple therapy in mCSPC - which is the ideal partner for radiotherapy? And which patients should received irradiation?

What is your preferred sequence in 1st line treatment and how you treat after progress?

Best of Bladder: ddMVC increases DFS! Standard dissection SOC? FGFR targeting showing efficacy!

The beginning of a new era in urothelial cancer?!

Q-TWiST in the therapy of aUC

New SoC option for metastatic bladder cancer

First line in cisplatin-ineligible advance urothelial cancer: It´s getting busy out there

New standard for MIBC

Enfortumab vedotin + pembrolizumab 1stL in cisplatin-ineligible patients

FGFR inhibition

Targeted therapies in advanced urothelial cancer: The renaissance?!

Extent of lymphadenectomy in cystectomy

Best of Bladder: ddMVC increases DFS! Standard dissection SOC? FGFR targeting showing efficacy!

Terapias dirigidas al cáncer urotelial avanzado: ¡¿El renacimiento?!

Nouvelles options de soins standard pour le cancer de la vessie métastatique

Primera línea en cáncer urotelial avanzado no elegible para cisplatina: Hay mucho trabajo ahí fuera

The efficacy of neo-adjuvant therapy (ddMVAC, Cisplatinum)

Update EV/Pembro, Avelumab Maintenance

The efficacy of FGFR targeting

Long term follow up in advanced renal cell cancer: Is everything clear, yet?

The impact of microbiome and supplements on therapy efficacy

Non ccRCC: how should we treat patients today?

Primary endpoint not reached: what do we learn from CONTACT-03 results?

Long-term follow-up for IO/TKI in mRCC

New standard for 2nd line RCC?

1st Line therapy RCC: which combination to choose?

IO rechallenge in mRCC

News from the adjuvant

Update and take home message of 1st Line mRCC

New data non ccRCC

Lenvatinib + pembrolizumab in non-clear cell renal cell carcinoma

ADAURA: Osimertinib improves survival in the treatment of EGFRm rNSCLC

The value of perioperative chemo-IO in rNSCLC and the importance of staging

Adjuvant and neoadjuvant strategies in resectable NSCLC

Role of periopertative IO confirmed

EGFR testing necessary in the adjuvant setting

Adjuvant IO in KRASm patients

More options in the perioperative setting

Confirmation of neoadjuvant immunotherapy

Perioperative treatment

ADAURA - results and controversies

A new standard of care for operated patients with eGFRmut adenocarcinoma

OS benefit from EGFR receptor TKI

A chemo-free preop. IO strategy?

A new standard of care

ADAURA - Discussion closed?

CheckMate 9LA: 4‑year clinical update

Induction options in the perioperative setting

Added benefit of perioperative chemo/IO in stage 2-3b NSCLC

Which should we prefer: neoadjuvant, adjuvant or perioperative chemo/IO?

An imperfect analysis, but perfect results

Another neoadjuvant chemo/IO option

Más opciones en el entorno perioperatorio

Toegevoegde waarde van periperatief chemo-immuno bij stadium II-IIIB NSCLC

Rolle der periopertativen IO bestätigt

Un nouveau standard therapeutique pour les patients opérés d’un adenocarcinome EGFR muté

ADAURA- discussie gesloten?

Que devrions-nous préférer: traitement néoadjuvant, adjuvant ou chimio/IO périopératoire?

Stratégies adjuvantes et néoadjuvantes dans le CBNPC résécable

Update on KRASG12Cm treatment options - how to proceed?

Zorifertinib: an option when osimertinib is not available

TTF-treatment requires further studies

Sotorasib: clear clinical benefit, but short follow-up time

Does ADC + chemo + IO replace the existing concepts?

Pembro + chemo in pts with TKI-resistant EGFRm / Sunvozertinib - a drug for Exon20 insertions

IO in EGRF positive patients post TKI

LUNAR: TTF medical device shows OS-benefit, but more information needed

ADC + ICI ± Pt-CT in patients with aNSCLC

Stopping treatment is ok

CORRELATE - a real world analysis

TROP2-ADC shows high response rates in 1L-combination therapy, but safety must be observed

Hyperfractionation - an interestingh concept, but not for every patient

New data from another BiTE

Can we incoporate biomarkers in SCLC treatment?

A positive trial with no impact

Hyperfractionated radiotherapy for SCLC

More BiTEs, more possibilities

Treatment strategies in SCLC

Stratégies de traitement dans le SCLC

Kunnen we biomarkers gebruiken om behandeling te selecteren voor SCLC?

Más BiTEs, más posibilidades

ONCOalert (inclusive patient advocates) consensus on the results of the PROspect trial

Immune checkpoint inhibitors in malignant mesothelioma

No practice-changing data in mesothelioma, other studies to await

Immun-Checkpoint-Inhibitoren beim malignen Mesotheliom